8-K: Immunic's IMU-856 Shows Promise in Celiac Disease and Weight Management with GLP-1 Increase

Immunic's IMU-856 demonstrated a dose-dependent increase in GLP-1 levels in celiac disease patients and reduced body weight gain in preclinical studies, suggesting potential as an oral treatment for weight management.

Summary

• Immunic, Inc. announced positive data for IMU-856, an oral small molecule modulator targeting SIRT6.
• A post-hoc analysis of a phase 1b clinical trial in celiac disease patients showed a dose-dependent increase in glucagon-like peptide-1 (GLP-1) levels with IMU-856.
• Preclinical in vivo testing also revealed a dose-dependent reduction of body weight gain and food consumption with IMU-856.
• The company believes these findings suggest IMU-856 could be a potential oral treatment option for weight management.
• Immunic is planning to further evaluate the findings and assess next steps for the IMU-856 program, including potential phase 2 clinical testing.
• The company hosted a live webinar and presented the data at the 19th Congress of the European Crohn's and Colitis Organisation on February 20, 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical and preclinical data for IMU-856, suggesting potential in treating celiac disease and weight management. The management's comments are optimistic, and the company is moving forward with further clinical testing. However, risks associated with drug development and regulatory approval are acknowledged.

Positives

• IMU-856 shows potential as an oral treatment option, offering a more convenient alternative to injectable incretin mimetics.
• The observed increase in GLP-1 levels with IMU-856 compares favorably to the typical physiological increase after a meal.
• IMU-856 targets SIRT6, which may result in a broader, more physiologic activation of enteroendocrine hormones.
• The company is preparing for further clinical testing of IMU-856.
• The company believes that IMU-856 may have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications.

Risks

• The forward-looking statements are subject to substantial risks and uncertainties.
• The results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.
• The company's ability to achieve its plans depends on the availability of sufficient financial and other resources.
• The drug development and regulatory approval process are subject to risks.
• The company faces competition from other products and technological changes.

Future Outlook

Immunic plans to further analyze the findings and assess next steps for the IMU-856 program, including potential phase 2 clinical testing, with the goal of developing an oral treatment option for obesity.

Management Comments

• Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, noted that IMU-856's target, SIRT6, is highly expressed in cells of the bowel wall, including enteroendocrine cells, which produce gastrointestinal hormones such as GLP-1 and gastric inhibitory peptide (GIP).
• Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, stated that the newly released clinical and preclinical data demonstrating IMU-856's potential positive effect on GLP-1 and food consumption is an exciting development for Immunic's oral small molecule program.
• Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, stated that if the effects reported today can be confirmed in further clinical trials, their convenient, once-daily small molecule tablet may represent an oral treatment option for obesity.

Industry Context

The announcement is relevant to the growing market for obesity treatments, which is expected to reach over $170 billion globally by 2031, and highlights the potential of oral small molecule therapies as alternatives to injectable incretin mimetics.

Comparison to Industry Standards

• The document mentions that currently available incretin mimetics are delivered via subcutaneous injection and focus on one or two enteroendocrine hormones.
• Immunic hypothesizes that the SIRT6 modulation approach may result in a broader, more physiologic activation of enteroendocrine hormones.
• The company believes that IMU-856 may replicate the natural effect after eating, with data from the phase 1b clinical trial in celiac disease patients showing, under fasting conditions, a dose-dependent increase of naturally occurring GLP-1 levels of up to 250 % versus placebo, which compares favorably to the typical physiological 2-3 times increase in GLP-1 in healthy humans after a meal.

Stakeholder Impact

• Shareholders may see potential for increased value due to the positive data and potential market opportunity.
• Employees may be impacted by the company's plans for further clinical testing and development of IMU-856.
• Patients with celiac disease and those seeking weight management solutions may benefit from the potential development of IMU-856 as an oral treatment option.

Next Steps

• Immunic will continue to analyze the findings and assess any next steps.
• The company is preparing for further clinical testing of IMU-856.
• Immunic will explore further the potential of SIRT6 modulation to result in a broader, more physiologic activation of enteroendocrine hormones.

Key Dates

Keywords

IMU-856, GLP-1, SIRT6, celiac disease, weight management, Immunic, clinical trial, preclinical data, oral treatment, autoimmune diseases, inflammatory diseases